Conference Overview

With the augmented incidence of diseases, and the non-medical use of prescription drugs, the incidence of drug abuse has increased enormously in the recent years, which is apparent with the excess documentation of adversities and drug toxicities. In this context, the drug safety and pharmacovigilance has emerged as a dynamic clinical and scientific discipline to provide adequate information and ensure health safety by the joint interaction of doctors and patients in choosing appropriate treatment method and drug. However, evidences suggest though avoidable, the adverse drug reactions (ADRs) to medicines continue to be the bigger life risk. In England, ADR was responsible for up to 6% of hospital admissions, carrying a mortality of 2% and costing the NHS £466 million per annum (€654 million, US$ 602 million) in 2004. In some countries, ADR is ranked among the top 10 leading cause of mortality. The concept of drug safety and pharmacovigilance has evolved considerably and is highly necessary to keep the severity of ADR under check. In order to prevent or to reduce harm to patients and improve public health, it is vital to develop and practice mechanisms for evaluating and monitoring the safety of medicines in clinical use.  Pharmacovigilance brief the potential implications of such trends on the evolution of the science. 

However, these days it is confronting issues to develop a better health care system in this global pitch. Some of the major challenges include globalization, web-based sales and information, broader safety concerns, public health versus pharmaceutical industry economic growth, monitoring of established products, developing and emerging countries, attitudes and perceptions to benefit and harm, outcomes and impact, etc. 

 

The Pharmacovigilance World 2022 conference will provide a platform for the participants to discuss, share and stay updated with present state of affairs in Pharmacovigilance and Drug safety, and how it contributes to the public health. It will also allow all its participants to interact with the experts, discuss the various developments, challenges faced and innovations in the field. Our Pharmacovigilance conferences are known for bringing the world-class leaders together to connect, learn and network. The conference will bring-forth the participants and the representatives from various fields of pharmacovigilance and drug safety under a common umbrella, and will provide them an opportunity to network with various industry professionals including pharmaceuticals, biologics, devices, CROs and PV service providers.

 

It gives us a great pleasure in welcoming you to the Pharmacovigilance World 2022 conference.


Conference Streams Include

 

 

Global PV & Methodologies

Data management & Analytics in PV

PV Automation, AI & Machine Learning

Safety Signals & Management

Pharmacovigilance Regulations

Risk
Management

Patient Centric Drug Safety

Case
Management

Quality &
Compliance

Pharmacovigilance Outsourcing

Medical Devices Safety

Adverse Drug Reactions

 

 

KEY DISCUSSIONS WE'LL BE EXPLORING

  • Pharmacovigilance and globalization
  • Pharmacovigilance in a pandemic world
  • Women and child health care medicines and pharmacovigilance
  • Patient-centric approaches in PV
  • Pharmacovigilance legislation and regulations
  • Harmonization and pharmacovigilance
  • Advanced therapeutic techniques and pharmacovigilance
  • Pharmacovigilance and data management and eudravigilance
  • Post-marketing surveillance in pharmacovigilance
  • PV regulations and challenges
  • Benefit-risk management strategies
  • Risk management and minimization
  • Risk Evaluation and Mitigation
  • Adverse drug reactions reporting
  • Signal detection and post authorization safety
  • Good Pharmacovigilance Practices
  • Innovative approaches to drug safety
  • Strategies to improve PV
  • Real World Evidence in PV
  • Big data and AI in pharmacovigilance
  • Pharmacovigilance Workflows with AI & Automation
  • Other emerging technologies in PV

 

 

WHO SHOULD ATTEND PHARMACOVIGILANCE 2022

 

CEOs, CTOs, CIOs, Presidents, Vice Presidents, Directors, Heads & Managers, Scientific Advisors, Consultants and professionals who work for pharmaceutical, biotechnology & devices industries, CROs and service providers involved in Pharmacovigilance and Drug safety.


Attendees includes Chief Data Officer, VPs, GMs, Directors, Heads and Managers of

  • Pharmacovigilance
  • Safety & Risk management
  • Drug safety
  • PV Compliance
  • Safety Surveillance
  • Medical Affairs
  • Regulatory Affairs
  • Inspection and Audit
  • Pharmacoepidemiology
  • Post-market studies
  • Medical product safety assessment
  • Drug Research & Development
  • Clinical Pharmacology
  • Medical information
  • Contract outsourcing service providers
  • Health outcomes
  • Sales and Marketing

 

 

 

 

pharmaceutical companies

Speakers

VIEW ALL

There are plenty of opportunities to position yourself as a thought leader & showcase your company.

For enquiries on speaker opportunities please e-mail to [email protected]

Become a Speaker


Tuesday - 22nd November 2022 (Time Zone - GMT)

  • 09:20
  • Welcome Address & Platform Orientation - Orientation will focus on how to access and navigate the virtual conference platform for Live Sessions & Interactive Networking

  • 09:35
  • Chairperson’s opening remarks

      Watch Session
    Michael Ramcharan

    Michael Ramcharan Managing Director
    Reumat Consulting

  • 09:45
  • Ways to build successful PV partnerships in in-licensing scenarios and the role of PV in due-diligence processes

      Watch Session   Presentation
    Andreas Osanger

    Andreas Osanger Director - Therapeutic Area Lead Nephrology
    CSL Vifor

  • 10:45
  • Benefit-risk assessment of isoniazid preventive therapy in people living with HIV in Eritrea

      Watch Session   Presentation
    Mulugeta Russom

    Mulugeta Russom Pharmacoepidemiologist and Pharmacovigilance Specialist Head
    Eritrean Pharmacovigilance Centre

Drug Safety Strategies & Pharmacovigilance

  • 11:10
  • Panel Discussion - An Integrated care: Effective Implementation of vigilances systems

    • Separated vigilance systems can lead to the emergence of divergence in terms, definitions, variety of reporting forms and methods and the build of specific databases where cross analysis is no more possible.
    • To be more proactive and innovative in PV and to ensure that emerging problems are promptly recognized and solutions are effectively communicated
    • This integrated approach is very useful, especially for emerging countries to strengthen regulatory processes and to promote high standards of product vigilance for the protection of the health and safety of Citizens
      Watch Session
    Michael Ramcharan

    Michael Ramcharan Managing Director
    Reumat Consulting

    Andreas Osanger

    Andreas Osanger Director - Therapeutic Area Lead Nephrology
    CSL Vifor

    Siva Kumar

    Siva Kumar Global Phv Surveillance Physician Sr Manager, Medical Scientific Unit
    Teva Pharmaceuticals

    Siddhant Ekale

    Siddhant Ekale Enterprise Architect – Clinical Data Management

Safety Signals & Risk Management

  • 12:10
  • Risk minimization and management

    • Assessment with comprehensive data quality
    • Compliant safety system (GxP compliant, inspection-ready system)
    • Safety signals, effective trials, strategic risk assessment decisions
      Watch Session   Presentation
    Klaudija Marijanovic Barac

    Klaudija Marijanovic Barac EU & UK QPPV deputy
    Teva Pharmaceuticals

  • 12:35
  • Virtual Luncheon & Networking - Visit Exhibitor Booths & Network with your peers in our Lounge (Face to Face Video Chats)

     

                

  • 13:40
  • Fireside Chat - REMS Compliance and Inspection Readiness

      Watch Session
    Michael Ramcharan

    Michael Ramcharan Managing Director
    Reumat Consulting

    Nancy Dubois

    Nancy Dubois Head of Global Patient Safety US Region
    EMD Serono, Inc.

    Kal Elhoregy

    Kal Elhoregy Director, Risk Evaluation and Mitigation Strategies
    Amneal Pharmaceuticals

    Iva Galic

    Iva Galic Pharmacovigilance Inspector Expert
    HALMED

  • 14:10
  • Assessing the Quality of ICSRs & the Impact on causality assessment and signal evaluation

      Watch Session
    Maria De Los Angeles Hernandez Loli

    Maria De Los Angeles Hernandez Loli Patient Safety Lead Cluster Ecuador - Peru
    Boehringer Ingelheim

  • 14:40
  • Case Study: Additional Risk Minimisation Measures from planning to execution

      Watch Session
    Eman Gomaa

    Eman Gomaa MEA PV Hub Lead
    AbbVie

  • 15:05
  • Visit Virtual Exhibitor Booths/Speed Networking at our Exclusive Lounge (Face to Face Video chat with Exhibitors and other attendees)

     

         

  • 15:20
  • The Safety Platform of Tomorrow in Production Today: Advancing Patient Safety through Innovation and Intelligence

      Watch Session
    Beena Wood

    Beena Wood Senior Vice President, Product Marketing
    ArisGlobal

    Elizabeth Smalley

    Elizabeth Smalley Director, Product Management, Data & Analytics
    ArisGlobal

Quality Assurance and Regulatory Compliance

  • 15:50
  • Why pharmacovigilance sometimes fails and how to bridge the gaps?

      Watch Session   Presentation
    Nancy Dubois

    Nancy Dubois Head of Global Patient Safety US Region
    EMD Serono, Inc.

  • 16:15
  • PSMF – Pharmacovigilance system master file

    • PSMF summary design, role of QPPV and managing audits.
    • Responsibilities of stakeholders.
    • Accessibility of PSMF and Transparency and ensuring compliance
    • Challenges in the managing data collection, audit information and documenting changes in logbooks, transferring information to license partners or third parties
      Watch Session
    Tea Babic

    Tea Babic Director, Head of PV Audits and Inspections Deputy Head of PV Compliance Global Patient Safety and Pharmacovigilance
    Teva Pharmaceuticals

  • 16:40
  • Cross-Functional Initiatives for Safety, Risk Management, and Pharmacovigilance Activities Across the Product’s Lifecycle

    • Increase transparency and improve awareness in your communication for Safety, Risk Management, and Pharmacovigilance across the product’s lifecycle
    • Bring value to cross functional approaches within safety governance (SMT and SAC), preparing aggregate reports (DSUR/ PBRER), safety surveillance and core data sheet etc.

Outsourcing & Vendor Management

  • 17:05
  • Build Effective Metrics for Vendor Oversight

      Watch Session
    Julia Appelskog

    Julia Appelskog EU QPPV, Head of EU QPPV Office
    Novavax

  • 17:30
  • Safety-Radar: towards autonomous reasoning in investigative toxicology. Including patients' genetics data in assessments of adverse events

    • Architecture of Safety-Radar – a system for evaluating drug safety.
    • The platform will support automated reasoning and serendipitous discovery of new 'facts' or interesting and testable hypotheses
    • Strategies of how to integrate and provide high-value AI-ready data sources and how to develop (semi) autonomous reasoning agents.
      Watch Session
    Marcin Von Grotthuss

    Marcin Von Grotthuss Associate Director, Machine Learning
    Takeda

  • 17:55
  • Chairperson’s closing remarks

      Watch Session
    Michael Ramcharan

    Michael Ramcharan Managing Director
    Reumat Consulting

  • 18:05
  • Virtual Networking - Catch-up with your peers in social lounge


Wednesday - 23rd November 2022 (Time Zone - GMT)

  • 09:20
  • Welcome Address & Platform Orientation - Orientation will focus on how to access and navigate the virtual conference platform for Live Sessions & Interactive Networking

  • 09:35
  • Chairperson’s opening remarks

      Watch Session
    Michael Ramcharan

    Michael Ramcharan Managing Director
    Reumat Consulting

Automation, AI & Data Management

  • 10:45
  • Impact of AI & Machine learning on Pharmacovigilance and Drug Safety

    • Ever expanding data and its safety
    • Importance and application of AI
    • Improving speed, accuracy and reliability using AI
      Watch Session   Presentation
    Robert Di Giovanni

    Robert Di Giovanni Global Project Safety Lead
    Novartis

  • 11:10
  • Patient involvement throughout the product lifecycle

    • Evolution of patient involvement 
    • Utilisation of new technologies
    • How Pharmacovigilance can support patient involvement 
    • Patient safety reporting
    • Preferred communication methods - mind the gap
      Watch Session   Presentation
    Yvonne Nanciu

    Yvonne Nanciu Country Head Pharmacovigilance Germany
    Bayer

  • 11:35
  • PV Inspections: Sharing knowledge, Increasing collaboration and engagement

    • how to structure regular gap analysis activities and how it can support inspection resdiness
    • how should PV and QPPV involved in risk based approach audits management
      Watch Session   Presentation
    Valentina Mancini

    Valentina Mancini Senior Director Pharmacovigilance, QPPV
    Shionogi

  • 12:25
  • Virtual Luncheon & Networking - Visit Exhibitor Booths & Network with your peers in our Lounge (Face to Face Video Chats)

     

                

  • 13:10
  • Use of real-world data to conduct rapid, non-protocolized signal assessment

      Watch Session   Presentation
    William Blumentals

    William Blumentals Sr. Director, Head of Pharmacoepidemiology in Specialty Care
    Sanofi

  • 13:35
  • ICH in Brazil: New PV Regulation following Incorporation of ICH Guidelines

      Watch Session   Presentation
    Raphael Elmadjian Pareschi

    Raphael Elmadjian Pareschi Head of Drug Safety Brazil / Patient Safety Lead
    Roche

  • 14:00
  • Perspectives on Benefit risk Assessment for Drugs

      Watch Session
    Siva Kumar

    Siva Kumar Global Phv Surveillance Physician Sr Manager, Medical Scientific Unit
    Teva Pharmaceuticals

  • 14:25
  • Panel Discussion – The future of pharmacovigilance: How technology will change the way we monitor drugs

    • The future of pharmacovigilance will be more automated
    • AI will play a big role in data management and analysis
    • The use of technology will increase speed and accuracy
      Watch Session
    Michael Ramcharan

    Michael Ramcharan Managing Director
    Reumat Consulting

    Yvonne Nanciu

    Yvonne Nanciu Country Head Pharmacovigilance Germany
    Bayer

    Stephanie Tcherny-Lessenot

    Stephanie Tcherny-Lessenot Global Head of Benefit-Risk Evaluation
    Sanofi

    Ashraf Youssef

    Ashraf Youssef Senior Medical Director, Global Post Marketed Products, Global Safety Lead
    Takeda

    Christina Barker

    Christina Barker Senior Director, Product Management, Safety
    ArisGlobal

  • 15:00
  • Visit Virtual Exhibitor Booths/Speed Networking at our Exclusive Lounge (Face to Face Video chat with Exhibitors and other attendees)

     

         

Case Processing & Patient Centric Approach

  • 15:20
  • Importance of Quality Case Processing in Pharmacovigilance

      Watch Session
    Laura Arce Mora

    Laura Arce Mora Country Safety Lead
    Pfizer

  • 15:45
  • Designing a Patient Centred Pharmacovigilance System

      Watch Session
    Agustina Zilifian

    Agustina Zilifian Regional Patient Safety Head
    Boehringer Ingelheim

  • 16:10
  • Compliance, the tools to be used, the continuous oversight and need for improvement

      Watch Session   Presentation
    Marco Colombati

    Marco Colombati Corporate Pharmacovigilance Compliance Specialist
    Italfarmaco SpA

  • 16:35
  • Effectiveness of Risk Minimisation Measures

      Watch Session   Presentation
    Zeljana Margan Koletic

    Zeljana Margan Koletic Head of Pharmacovigilance and Rational Pharmacotherapy Department
    Agency for Medicinal Products and Medical Devices

  • 17:25
  • Developing Value-Based Partnerships

    • Establishing a clear understanding of the goals and objectives of the partnership
    • Defining the roles and responsibilities of each partner
    • Negotiating and formalizing agreements between partners
    • Monitoring and evaluating the partnership performance on an ongoing basis
      Watch Session   Presentation
    Cinthya Galicia Quintanar

    Cinthya Galicia Quintanar Senior Manager, Country Safety Lead
    Pfizer

  • 17:50
  • Chairperson’s closing remarks & End of Conference

      Watch Session
    Michael Ramcharan

    Michael Ramcharan Managing Director
    Reumat Consulting

What do the Pass Include


  •  C-Suite keynote sessions & Panel Discussions
  •  Full 2-day live event Access
  •  Interactive live Video chat
  •  Interactive Social lounge with individual tables for discussions & Exchange of Information
  •  Q&A Session and polling
  •  Messaging meetings and networking with Industry Experts and Peers
  •  Access to Virtual expo (including videos, reports and articles from solution providers),
  •  Receiving Handouts
  •  On demand event recordings until 1 month
  •  Certificate for attending

BRING YOUR TEAM
Delegate Registration

Corvus Global Events recognises the value of learning in teams. There's so much great content!!!

Bring your team and get an extra discount. There are special group packages available. Please email to [email protected]for more details.

register now

PARTNERS

Partnerships typically involve an exchange of value and frequently include online content, PR, advertising, online & event branding.

For enquiries please e-mail to [email protected]

VIRTUAL PLATFORM

 

Our interactive platform has many rich features and they are a great experience for the users with Networking Video Chat, Polling, Raise Hand, Virtual Exhibitor booths with waiting room/tables, Q&A Sessions with industry experts, virtual chat, Peer to Peer connect at Social Lounge and Handout Bag

Stay Informed

Subscribe today to receive news on latest updates,
offers and upcoming conferences via email

For general conference and registration enquires please contact the below email id or fill out the form

Enquire now